| CAS | 867021-83-8 |
| Sequence | H-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro-OH |
| Sequence Single | SALLRSIPAPAGASRLLLLTGEIDLP |
| Molecular Formula | C119H206N32O35 |
| Molecular Weight | 2645.14 |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Application | Alzheimer’s Disease |
| Description | Colivelin is a hybrid peptide which mediates neuroprotection against Alzheimer’s disease (AD)-relevant insults. It is composed of activity-dependent neurotrophic factor (ADNF) C-terminally fused to AGA(C8R)HNG17, a potent humanin derivative. Colivelin completely suppressed death induced by overexpressing familial AD-causative genes and amyloid β-protein (1-43) at a concentration of 100 fM. Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro. Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin has the potential for the treatment of alzheimer’s disease and ischemic brain injury. |
| References | 1. Chiba et al (2005) Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer’s disease-relevant insults in vitro. Tomohiro Chiba et al., Neurosci. 25 10252 PMID: 16267233 2. A novel peptide, colivelin, prevents alcohol-induced apoptosis in fetal brain of C57BL/6 mice: signaling pathway investigations. Sari et al (2009), Neuroscience 164 1653 PMID: 19782727 3. Nasal colivelin treatment ameliorates memory impairment related to Alzheimer’s disease. Yamada et al (2008). Neuropsychopharmacology 33 2020 PMID: 17928813 |